WallStSmart

Broadcom Inc (AVGO)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Broadcom Inc generates 16% more annual revenue ($68.28B vs $58.74B). AVGO leads profitability with a 36.6% profit margin vs 17.4%. AVGO appears more attractively valued with a PEG of 0.68. AVGO earns a higher WallStSmart Score of 76/100 (B+).

AVGO

Strong Buy

76

out of 100

Grade: B+

Growth: 7.3Profit: 9.5Value: 4.7Quality: 7.5
Piotroski: 6/9Altman Z: 1.59

AZN

Strong Buy

66

out of 100

Grade: B-

Growth: 6.7Profit: 8.0Value: 10.0Quality: 6.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AVGOSignificantly Overvalued (-32.6%)

Margin of Safety

-32.6%

Fair Value

$240.08

Current Price

$318.81

$78.73 premium

UndervaluedFair: $240.08Overvalued
AZNUndervalued (+32.8%)

Margin of Safety

+32.8%

Fair Value

$306.07

Current Price

$185.78

$120.29 discount

UndervaluedFair: $306.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVGO6 strengths · Avg: 9.3/10
Market CapQuality
$1.51T10/10

Mega-cap, among the largest globally

Return on EquityProfitability
33.4%10/10

Every $100 of equity generates 33 in profit

Profit MarginProfitability
36.6%10/10

Keeps 37 of every $100 in revenue as profit

Operating MarginProfitability
31.8%10/10

Strong operational efficiency at 31.8%

PEG RatioValuation
0.688/10

Growing faster than its price suggests

Revenue GrowthGrowth
16.4%8/10

16.4% revenue growth

AZN5 strengths · Avg: 9.0/10
Market CapQuality
$284.63B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
53.9%10/10

Earnings expanding 53.9% YoY

Return on EquityProfitability
22.8%9/10

Every $100 of equity generates 23 in profit

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$1.38B8/10

Generating 1.4B in free cash flow

Areas to Watch

AVGO3 concerns · Avg: 3.3/10
EPS GrowthGrowth
1.9%4/10

1.9% earnings growth

Altman Z-ScoreHealth
1.594/10

Distress zone — elevated risk

P/E RatioValuation
62.3x2/10

Premium valuation, high expectations priced in

AZN3 concerns · Avg: 3.3/10
P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AVGO

The strongest argument for AVGO centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 36.6% and operating margin at 31.8%. Revenue growth of 16.4% demonstrates continued momentum.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.

Bear Case : AVGO

The primary concerns for AVGO are EPS Growth, Altman Z-Score, P/E Ratio. A P/E of 62.3x leaves little room for execution misses.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

AVGO profiles as a growth stock while AZN is a value play — different risk/reward profiles.

AVGO carries more volatility with a beta of 1.26 — expect wider price swings.

AVGO is growing revenue faster at 16.4% — sustainability is the question.

AVGO generates stronger free cash flow (8.0B), providing more financial flexibility.

Bottom Line

AVGO scores higher overall (76/100 vs 66/100), backed by strong 36.6% margins and 16.4% revenue growth. AZN offers better value entry with a 32.8% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Broadcom Inc

TECHNOLOGY · SEMICONDUCTORS · USA

Broadcom Inc. is an American designer, developer, manufacturer and global supplier of a wide range of semiconductor and infrastructure software products. Broadcom's product offerings serve the data center, networking, software, broadband, wireless, and storage and industrial markets.

Visit Website →

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?